S&P TSX Capped Composite...

US Dollar vs CAD

Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

Get Started

HEPA Hepion Pharmaceuticals Inc

1.36

0.00 (0.00%)

May 01 2024 - Closed

Delayed by 15 minutes

Hepion Pharmaceuticals gets FDA fast track designation for CRV431 to treat liver disease

To read the full story on Seeking Alpha, click here.

Hepion Pharmaceuticals (NASDAQ:HEPA)
Historical Stock Chart
From Apr 2024 to May 2024

Click Here for more Hepion Pharmaceuticals Charts.

Hepion Pharmaceuticals (NASDAQ:HEPA)
Historical Stock Chart
From May 2023 to May 2024

Click Here for more Hepion Pharmaceuticals Charts.

Hepion Pharmaceuticals Inc News

Hepion Pharmaceuticals Initiates Wind-Down Activities in Phase 2b ‘ASCEND-NASH’ Trial
Friday 19 April 2024 (2 weeks ago) • GlobeNewswire Inc.

Form 8-K - Current report
Friday 16 February 2024 (2 months ago) • Edgar (US Regulatory)

Hepion Pharmaceuticals Announces Exercise of Warrants for Approximately $2.0 Million Aggregate Gross Proceeds
Friday 16 February 2024 (2 months ago) • GlobeNewswire Inc.

Form SC 13G - Statement of acquisition of beneficial ownership by individuals
Wednesday 14 February 2024 (3 months ago) • Edgar (US Regulatory)

Hepion Pharmaceuticals to Present at NASH-TAG 2024
Wednesday 3 January 2024 (4 months ago) • GlobeNewswire Inc.

Form 8-K - Current report
Wednesday 3 January 2024 (4 months ago) • Edgar (US Regulatory)

Hepion Pharmaceuticals Announces Restructuring Plan to Enhance Shareholder Value and Management Changes
Thursday 7 December 2023 (5 months ago) • GlobeNewswire Inc.

Hepion Pharmaceuticals to Present at the 7th Obesity & NASH Drug Development Summit
Tuesday 28 November 2023 (5 months ago) • GlobeNewswire Inc.

Hepion Pharmaceuticals Announces Major Reductions in Liver Stiffness with Rencofilstat Treatment in 17-week Phase 2 Study of Advanced (F3) MASH Liver Disease
Monday 13 November 2023 (6 months ago) • GlobeNewswire Inc.

Hepion Pharmaceuticals Schedules Conference Call to Review Additional Efficacy Data from Phase 2 ‘ALTITUDE-NASH’ Liver Function Trial of Rencofilstat
Friday 10 November 2023 (6 months ago) • GlobeNewswire Inc.

Form EFFECT - Notice of Effectiveness
Wednesday 8 November 2023 (6 months ago) • Edgar (US Regulatory)

Hepion Pharmaceuticals’ Rencofilstat Demonstrates Anti-Cancer Activity in Hepatitis C-Associated Cancer Model
Wednesday 25 October 2023 (6 months ago) • GlobeNewswire Inc.

More Hepion Pharmaceuticals Inc News Articles

Global Developments (PK)

FBEC Worldwide (PK)

Mullen Automotive

Atacama Resources (PK)

NaturalShrimp (QB)

NioCorp Developments

Branded Legacy (PK)

Federal Home Loan Mortgage (QB)

International Star (PK)

Fannie Mae (QB)

MicroCloud Hologram

Tonner One World (PK)

Delayed Upgrade Clock

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions